II2Q.F · InspireMD, Inc

-

Please sign in to comment on II2Q.F

1 Comment

Admin

4 years ago

InspireMD, Inc is currently in a long term downtrend where the price is trading 4.1% below its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.8.

InspireMD, Inc's total revenue sank by 84.4% to $158K since the same quarter in the previous year.

Its net income has dropped by 50.7% to $-4M since the same quarter in the previous year.

Finally, its free cash flow fell by 39.5% to $-2M since the same quarter in the previous year.

Based on the above factors, InspireMD, Inc gets an overall score of 1/5.

Sector	Healthcare
Industry	Medical Devices
Exchange	F
CurrencyCode	EUR
ISIN	None

Dividend Yield	None
PE Ratio	None
Target Price	None
Beta	1.99

ABOUT

InspireMD, Inc

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms and seals the aneurysms. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv, Israel.

II2Q.F · InspireMD, Inc

-

InspireMD, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest InspireMD, Inc using a moving average strategy